检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李艺[1] 崔恒[1] 沈丹华[2] 赵彦[1] 魏丽惠[1] 钱和年[1]
机构地区:[1]北京大学人民医院妇科肿瘤中心,100044 [2]北京大学人民医院病理科,100044
出 处:《中华妇产科杂志》2003年第2期81-84,共4页Chinese Journal of Obstetrics and Gynecology
摘 要:目的 探讨影响卵巢交界性上皮性肿瘤预后的临床及病理因素。方法 回顾性分析我院 1973年 1月~ 2 0 0 0年 12月收治的 3 4例卵巢交界性上皮性肿瘤及 3 0例Ⅰ期卵巢上皮性癌 (卵巢癌 )患者的临床病理资料 ,并按 1999年WHO的组织学标准核对诊断。结果 64例患者中 ,符合卵巢交界性上皮性肿瘤诊断者 3 7例 ,其中 6例微浸润的卵巢交界性上皮性肿瘤曾被误诊为Ⅰ期卵巢癌 ,1例卵巢交界性上皮性肿瘤为非浸润性腹膜种植。卵巢癌组织学类型以黏液性和浆液性为主 ,95 %为国际妇产科联盟 (FIGO)临床分期的Ⅰ期。患者均行手术治疗 ,其中 11例行保守手术者复发率为9% ;2 6例肿瘤细胞减灭术后给予环磷酰胺 +阿霉素 +顺铂 (CAP)方案为主的化学药物治疗 (化疗 )。已随访 5年、10年患者的生存率均达 10 0 %。经多因素相关分析显示 ,组织学类型和是否化疗是影响预后的因素 (P <0 0 1)。结论 卵巢交界性上皮性肿瘤患者以手术治疗为主 。Objective To study the relationship between clinical pathological factors and prognosis. Methods Thirty-four cases with borderline ovarian tumors (BOT) and 30 cases with stage Ⅰ ovarian epithelial cancer admitted in our hospital from Jan.1973 to Dec.2000 were studied retrospectively. All the cases were diagnosed according to the International Histological Classification and Staging of Ovarian Tumors (WHO,1999). Results Thirty-seven cases were finally diagnosed of BOT,6 cases with 'microinvasive' had been misinterpreted as stageⅠ ovarian cancer and one had 'non-invasive peritoneal implants'. Serous(38%) and mucinous (51%) tumors were dominant type of BOT and 95% of tumors were at stage Ⅰ (International Feberation of Gynecology and Obstetrics,FIGO). All patients were operated, 11 cases given conservative surgery with a recurrence rate of 9%, 26 cases had adjuvant chemotherapy, cyclophosphamide+adriamycin+cis-platinum used mostly. 5-year and 10 year survival rates were both 100%. The prognosis of BOT is related to pathology and adjuvant therapy. Conclusion Surgery is the main treatment choice of BOT, and the criteria of chemotherapy must be adequately used.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222